Von Willebrand disease, hemophilia A and B, and other factor deficiencies

International Anesthesiology Clinics

Volumn 42, Issue 3, 2004, Pages 59-76

  Lee, Jae Woo ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 13 CONCENTRATE; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 COMPLEX; BLOOD CLOTTING FACTOR 9 CONCENTRATE; CYCLOPHOSPHAMIDE; DESMOPRESSIN; FRESH FROZEN PLASMA; IMMUNOGLOBULIN; KOATE DVI; KONYNE 80; PROFILNINE SD; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; THROMBIN;

ARTERY THROMBOSIS; BLOOD CLOTTING FACTOR 10 DEFICIENCY; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BLOOD CLOTTING FACTOR 5 DEFICIENCY; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BLOOD CLOTTING FACTOR DEFICIENCY; CLINICAL FEATURE; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DYSPROTHROMBINEMIA; FACE EDEMA; HEADACHE; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HYPONATREMIA; HYPOPROTHROMBINEMIA; HYPOTENSION; LUNG EMBOLISM; NAUSEA; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SEIZURE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOPHLEBITIS; THROMBOSIS; TREATMENT INDICATION; VON WILLEBRAND DISEASE;

ANESTHESIA, GENERAL; COAGULATION PROTEIN DISORDERS; HEMOPHILIA A; HEMOPHILIA B; HUMANS; SURGICAL PROCEDURES, OPERATIVE; VON WILLEBRAND DISEASE;

EID: 3242726768     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004311-200404230-00007     Document Type: Review

References (67)

1. Ginsburg D. Von Willebrand disease. In: Beutler E, Coller BS, Lichtman MA, et al, eds. William's Hematology. 6th ed. New York, NY: McGraw-Hill; 2001;1813-1828.
2. Hambleton J. Advances in the treatment of von Willebrand disease. Semin Hematol. 2001;38(suppl 9):7-10.
3. Cobas M. Preoperative assessment of coagulation disorders. Int Anesthesiol Clin. 2001;39:1-15.
4. Yamamoto K, de Waard V, Fearns C, et al. Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo. Blood. 1998;92:2791-2801.
5. Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69:1691-1695.
6. Tefferi A, Nichols WL. Acquired von Willebrand disease: concise review of occurrence, diagnosis, pathogenesis, and treatment. Am J Med. 1997;103:536-540.
7. Rinder MR, Richard RE, Rinder HM. Acquired von Willebrand's disease: a concise review. Am J Hematol. 1997;54:139-145.
8. Rock G, Adamkiewicz T, Blanchette V, et al. Acquired von Willebrand factor deficiency during high-dose infusion of recombinant factor VIII. Br J Haematol. 1996;93:684-687.
9. Federici AB, Stabile F, Castaman G, et al. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood. 1998;92:2707-2711.
10. Delmer A, Horellou MH, Brechot JM, et al. Acquired von Willebrand disease: correction of hemostatic defect by high-dose intravenous immunoglobulins. Am J Hematol. 1992;40:151-152.
11. Gross S, Traulle C, Capiod JC, et al. Efficacy of high dose intravenous gammaglobulin in the management of acquired von Willebrand's disease during orthopaedic surgery. Br J Haematol. 1992;82:170-171.
12. Nitu-Whalley IC, Griffioen A, Harrington C, et al. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am J Hematol. 2001;66:280-284.
13. Mauz-Korholz C, Budde U, Korholz D, et al. DDAVP treatment in a child with von Willebrand disease type 2M. Eur J Pediatr. 1999;(suppl 3):S174-S176.
14. Derkay CS, Werner E, Plotnick E. Management of children with von Willebrand disease undergoing adenotonsillectomy. Am J Otolaryngol. 1996;17:172-177.
15. Allen GC, Armfield DR, Bontempo FA, et al. Adenotonsillectomy in children with von Willebrand disease. Arch Otolaryngol Head Neck Surg. 1999;125:547-551.
16. Shah SB, Lalwani AK, Koerper MA. Perioperative management of von Willebrand's disease in otolaryngologic surgery. Laryngoscope. 1998;108:32-36.
17. Mauz-Korholz C, Budde U, Kruck H, et al. Management of severe chronic thrombocytopenia in von Willebrand's disease type 2B. Arch Dis Childhood. 1998;78:257-260.
18. Nolan B, White B, Smith J, et al. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders. Br J Haematol. 2000;109:865-869.
19. Smith TJ, Gill JC, Ambruso DR, et al. Hyponatremia and seizures in young children given DDAVP. Am J Hematol. 1989;31:199-202.
20. Foster PA. A perspective on the use of FVIII Concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to DDAVP: results of an international survey. Thromb Haemost. 1995;74:1370-1378.
21. Hanna WT, Bona RD, Zimmerman CE, et al. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease. Thromb Haemost. 1994;71:173-179.
22. Slaughter TF, Mody, EA, Oldman HN Jr, et al. Management of a patient with type IIC von Willebrand's disease during coronary artery bypass graft surgery. Anesthesiology. 1993;78:195-197.
23. Smith MP, Rice KM, Bromidge ES, et al. Continuous infusion therapy with very high purity von Willebrand factor concentrate in patients with severe von Willebrand disease. Blood Coagul Fibrinolysis. 1997;8:6-12.
24. Ciavarella N, Schiavoni M, Valenzano E, et al. Use of recombinant factor VIIa (NovoSeven® in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis. 1996;26(suppl 1):150-154.
25. Roberts HR, Hoffman M. Hemophilia A and hemophilia B. In: Beutler E, Coller BS, Lichtman MA, et al, eds. William's Hematology. 6th ed. New York, NY: McGraw-Hill; 2001:1639-1652.
26. Oldenburg J, Schwaab R. Molecular biology of blood coagulation. Semin Thromb Hemost. 2001;27:313-324.
27. Cohen AJ, Kessler CM. Treatment of inherited coagulation disorders. Am J Med. 1995;99:675-682.
28. Lofqvist T, Nilsson IM, Petersson C. Orthopaedic surgery in hemophilia, 20 year's experience in Sweden. Clin Orthop. 1996;332:232-241.
29. Scott TA, Jackler RK, Koerper MA. Management of hemophilia in otolaryngologic surgery. Arch Otolaryngol Head Neck Surg. 1988;114:1445-1448.
30. Donmez A, Turker H, Sekerci S, et al. Dealing with a hemophilia A patient undergoing cerebral aneurysm surgery. J Neurosurg Anesthesiol. 1999;11:214-215.
31. Kobayashi M, Matsushita M, Nishikimi N, et al. Treatment of abdominal aortic aneurysm in a patient with hemophilia A: a case report and review of the literature. J Vasc Surg. 1997;25:945-948.
32. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol. 2001;38(suppl 4):44-51.
33. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol. 2001;38(suppl 4):52-59.
34. Hedner U. Recombinant factor VIIa (NovoSeven) as a hemostatic agent. Semin Hematol. 2001;38(suppl 12):43-47.
35. Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors, clinical relevance for patients with haemophila. Clin Pharmacokinet. 2001;40:815-832.
36. Schulman S, Varon D, Keller N, et al. Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb Haemost. 1994;72:403-407.
37. Martinowitz U, Schulman S. Review of pumps for continuous infusion of coagulation factor concentrates: what are the options? Blood Coagul Fibrinolysis. 1996;7(suppl 1): S27-S33.
38. Schulman S, d'Oiron R, Martinowitz U, et al. Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis. 1998;9 (suppl 1):S97-S101.
39. Longo G, Messori A, Morfini M, et al. Evaluation of factor VIII pharmacokinetics in hemophilia A subjects undergoing surgery and description of a nomogram for dosing calculations. Am J Hematol. 1989;30:140-149.
40. Tarantino M, Aledort L. On the treatment of hemorrhage in patients with hemophilia and associated inhibitors. Transfusion. 2001;41:1628-1629.
41. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost. 2000;26:425-432.
42. Kenet G, Lubetsky A, Gitel S, et al. Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VII. Blood Coagul Fibrinolysis. 2000;11 (suppl 1):S35-S38.
43. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (Novo Seven) in haemophilia patients with inhibitors undergoing surgery. Thrombosis Haemostasis. 1998;80:773-778.
44. Gringeri A, Santagostino E, Mannucci PM. Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody. Haemostasis. 1991;21:1-4.
45. Peerlinck K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor. Thromb Haemost. 1999;82:1775-1776.
46. Scharf R, Kucharski W, Nowak T. Surgery in hemophilia A patients with factor VIII inhibitor: 10 year experience. World J Surg. 1996;20:1171-1181.
47. Robbins D, Kulkarni R, Gera R, et al. Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy. Am J Hematol. 2001;68:184-188.
48. Sohngen D, Specker C, Bach D, et al. Acquired factor VIII inhibitors in nonhemophilic patients. Ann Hematol. 1997;74:89-93.
49. Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Cancer. 2001;91:1067-1074.
50. Roberts HR, Hoffman M. Hemophilia A and hemophilia B. In: Beutler E, Coller BS, Lichtman MA, et al, eds. William's Hematology. 6th ed. New York, NY: McGraw-Hill 2001:1652-1657.
51. Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res. 1999;95:S13-S17.
52. Hoots WK, Conlan MG. Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery. Am J Hematol. 1990;35:203-207.
53. Santagostino E, Mannucci PM, Gringeri A, et al. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery. Thrombosis Haemostasis. 1994;71:737-740.
54. Bardin JM, Sultan Y. Factor IX concentrate versus prothrombin complex concentrate for the treatment of hemophilia B during surgery. Transfusion. 1990;30:441-443.
55. Donahue BS, Emerson CW, Slaughter TF. Elective and emergency cardiac surgery on a patient with hemophilia B. J Cardiothorac Vasc Anesth. 1999;13:92-97.
56. White GC, Shapiro AD, Kurczynski EM, et al. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. Thromb Haemost. 1995;73:779-784.
57. Goldsmith JC, Kasper CK, Blatt PM, et al. Coagulation factor IX: successful surgical experience with a purified factor IX concentrate. Am J Hematol. 1992;40:210-215.
58. White G, Shapiro A, Ragni M, et al. Clinical evaluation of recombinant factor IX. Semin Hematol. 1998;35(suppl 2):33-38.
59. Schwaab R, Oldenburg J. Gene therapy of hemophilia. Semin Thromb Hemost. 2001;27:417-424.
60. Herzog RW, Yang EY, Couto LB, et al. Long term correction of hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nature Med. 1995;5:56-63.
61. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24:257-261.
62. Seligsohn U, White GC. Inherite d deficiencies of coagulation factors II, V, VII, XI, and XIII and the combined deficiencies of factor V and VIII and of the vitamin K-dependent factors. In: Beutler E, Coller BS, Lichtman MA, et al, eds. William's Hematology. 6th ed. New York, NY: McGraw-Hill; 2001:1617-1638.
63. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia. 1999;5:253-259.
64. Knight RD, Barr CF, Alving BM. Replacement therapy for congenital factor X deficiency. Transfusion. 1985;25:78-80.
65. Bolton-Maggs PH. Factor XI deficiency and its management. Haemophilia. 2000;6(suppl 1):100-109.
66. Castaman G, Ruggeri M, Rodeghiero F. Clinical usefulness of desmopressin for prevention of surgical bleeding in patients with symptomatic heterozygous factor XI deficiency. Br J Hoematol. 1996;94:168-170.
67. Broard PG, Losowsky MS, Miloszewski KJ. Factor XIII: inherited and acquired deficiency. Blood Rev. 1993;7:229-242.